COVID-19 Vaccine Trial Put On Hold Because of Possible Adverse Reaction
The New York Times is reporting that a study volunteer in the U.K. developed transverse myelitis.
One of the leaders in the race to develop a COVID-19 vaccine has suffered a setback because a participant in the vaccine’s phase 3 trial developed a serious condition that might be related to vaccine.
The New York Times is reporting that a study volunteer in the U.K. developed transverse myelitis, a condition characterized by inflammation of the spinal cord. According to an National Institute of Neurological Disorders and Stroke fact sheet about transverse myelitis, the causes can include a number of different autoimmune disorders, an abnormal immune response to cancer, and viral, bacterial, and fungal infections.
Stat broke the news about the possible adverse reaction and the pause in the enrollment in the AstraZeneca's phases 3 study yesterday.
In response to Stat's story, AstraZeneca put out a statement that said it had voluntarily paused vaccination. The statement described the stoppage as a “routine action, which has to happen whenever there is a potentially unexplained illness," and cautioned that in "large trials illnesses will happen by chance."
AstraZeneca announced on Aug. 31 that it was starting to enroll study volunteers in the United States with a goal of recruiting up to 30,000 participants. The trial is designed so some people are randomized to get two doses of the vaccine — known temporarily as AZD1222 — four weeks apart and others, a saline solution.
The Times reported that the vaccine, which was developed by University of Oxford researchers, is in phase 2/3 trials in England and phase 3 trials in Brazil, South African and the United States.
Women Pay More and Get Less from Employer Health Plans
June 19th 2025In a report by JPMorgan Chase's Morgan Health, it was found that 37% of women with employer-sponsored insurance said meeting their deductibles is difficult, and 36% reported that their plans didn’t cover care they expected—or paid less than anticipated.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Lenacapavir HIV PrEP: Not an AIDS Vaccine, but Vaccine Adjacent
June 19th 2025Experts and advocates say that twice-a-year HIV PrEP injections have the prevention potential of a vaccine — and that a once-a-year version of lenacapavir would be even better. But will Yeztugo be available to the people who would benefit most from HIV PrEP?
Read More
